Revolutionizing Disease Treatment: IsomAb Secures $7.5M in Seed Funding for Groundbreaking Isoform Specific Antibody Development

Exciting news from IsomAb Ltd as the company announces a successful funding round, raising an impressive $7,500,000. IsomAb is a pioneering biotech company dedicated to identifying and developing isoform-specific antibodies to address diseases with limited treatment options. With a unique approach, IsomAb is at the forefront of developing groundbreaking therapies. The company's flagship product, ISM-001, targets the VEGF-A165b isoform, showing promising results in inhibiting the growth factor critical for new blood vessel formation in ischemic disease patients. This recent funding will propel IsomAb's research and development efforts, further advancing their innovative pipeline of isoform-specific antibodies and bringing hope to patients in need of new treatment options.